JNJ Stock: A $100 Billion Milestone — But Is the Fortress Fully Priced?

JBHT Stock: J.B. Hunt Doubled on the Freight Turn — Too Late to Buy?

J.B. Hunt Transport (JBHT) Q2 2026 — J.B. Hunt Transport (JBHT), the freight and logistics bellwether, reported Q2 2026 adjusted EPS of $1.91, beating $1.71, with EPS inflecting up from $1.49 the prior quarter and operating margins improving — early signs the multi-year freight recession is turning. The stock popped ~8% to a fresh 52-week high (~$298), having more than doubled off its ~$130 low. But it now trades at ~46x trough / ~30x normalized earnings, right at the Street's ~$298 average target — the recovery is largely priced in. J.B. Hunt is a bellwether for the whole American economy — a freight and logistics giant (intermodal, dedicated fleets, brokerage, final mile) whose stock has just more than doubled off its low, betting a brutal multi-year freight recession is finally ending. Q2 2026 gave real evidence: adjusted EPS of $1.91 beat, and — the key point — earnings inflected from $1.49 to $1.91 quarter-over-quarter as volumes and pricing firmed. With huge operating leverage in intermodal, profits can climb fast off a trough. The catch is the price: the stock sits at a 52-week high after a ~130% run, trades near 46x trough / 30x normalized earnings, and Wall Street's average target (~$298) is right where it trades — analysts see almost no upside left. The easy money, buying the scary trough, has been made. Our cycle-adjusted fair value lands near $285, just below the ~$298 price. Our call: HOLD, 3/5 — a great operator riding a real recovery that's already in the price. Own it through the cycle if you like; we'd wait for a pullback toward the low $250s. Watch the freight-rate data. Not financial advice. THE CALL: HOLD (3/5, THE FREIGHT CYCLE IS TURNING — BUT IT'S ALREADY IN THE PRICE) — base-case value ~$285 vs ~$298 today. What to watch: a pullback toward the low $250s (a far better entry for the same recovery thesis) as the ideal add; on the upside, freight rates accelerating faster than the consensus would push earnings past mid-cycle — the risk is the recovery stalling at a 52-week high Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

UAL Stock: United Raised Guidance Through a $6B Fuel Hit — Buy It?

United Airlines (UAL) Q2 2026 — United Airlines (UAL) reported a strong Q2 2026: revenue up 16% YoY to $17.7B, adjusted EPS $1.99 (beat $1.91), unit revenue (TRASM) +12.1%, with premium revenue +16%, loyalty +11% and cargo +23%. Most notably, it RAISED full-year 2026 adjusted EPS guidance to $9.00-$11.00 despite absorbing nearly $6B more fuel cost. The stock (~$119, ~14% off its $139 high, ~12x forward) barely moved. The Street is bullish — a Buy consensus, target ~$155 (+30%). Airlines have destroyed shareholder value for decades — brutally cyclical, capital-hungry, at the mercy of fuel and labor. So is United, the best-run of the group, the exception? Its Q2 2026 was genuinely strong: revenue +16% to $17.7B, adjusted EPS $1.99 (beat), unit revenue +12%, and — the key point — it RAISED full-year guidance to $9-11 adjusted EPS while absorbing a nearly $6B fuel-cost increase. That's pricing power beating input costs. The engine is its premium strategy: premium-cabin revenue +16%, MileagePlus loyalty +11% (the closest thing to an airline moat), and a hard-to-replicate international network. The industry has consolidated to four disciplined carriers, and travelers are trading up to premium — right where United is strongest. At ~12x it's cheap, but we discount airline earnings for cyclicality: our cycle-adjusted fair value lands near $140 (vs $119), below the Street's $155. Our call: BUY, 3/5 — a cheap, well-run airline in a better-structured industry. Own it as a value bet; buy weakness, and watch the demand data, because in airlines the cycle is everything. Not financial advice. THE CALL: BUY (3/5, CHEAP AND EXECUTING — RAISED GUIDANCE THROUGH A FUEL SHOCK) — base-case value ~$140 vs ~$119 today. What to watch: unit revenue and premium demand holding up (pricing power intact); the risk that breaks it is any sign travel demand is rolling over or a fuel spike it can't pass through — buy weakness rather than chase strength Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

CTAS Stock: Cintas Popped 7% on Earnings — But It’s ~40x. Buy It?

Cintas (CTAS) Q4 FY2026 — Cintas (CTAS), the uniform-rental and facility-services compounder, reported fiscal Q4 2026: revenue up ~7% to $2.9B, adjusted EPS $1.29 (beat $1.24), operating margin over 23%. The stock popped ~7%. It's a wide-moat, recurring-revenue machine (route density, ~23% margins, cross-selling first aid/safety and fire protection) — one of the best-performing stocks of the past few decades. But near ~$206 (~9% off its $227 high) it trades at ~40x earnings for ~8-10% growth. The Street is split — a Hold consensus, target ~$231. Cintas is one of the most boring businesses in the market — renting uniforms and supplying mats, first-aid kits and fire extinguishers — and one of the best-performing stocks of the last few decades. It just beat again (fiscal Q4 revenue +7% to $2.9B, adjusted EPS $1.29, ~23% operating margin) and popped ~7%. The moat is route density: once its trucks serve a neighborhood, the next customer is nearly free, driving best-in-class margins and relentless, recurring-revenue compounding via new customers, cross-selling, and price. There's no turnaround to debate — the only question is the price. At ~40x earnings for ~8-10% growth, it's priced for perfection: our owner-earnings work lands fair value near $203, essentially right at the ~$206 price, with no margin of safety. Our call: HOLD, 3/5 — an elite compounder we'd love to own cheaper. Own it if you have it; wait for a market pullback toward the mid-$170s if you don't. Not financial advice. THE CALL: HOLD (3/5, AN ELITE COMPOUNDER, PRICED FOR PERFECTION) — base-case value ~$205 vs ~$206 today. What to watch: a broad market pullback that takes it toward the mid-$170s (a rare cheap entry), or growth reaccelerating above 10% (via cross-selling or M&A) that lets the ~40x multiple grow into itself; the risk is a de-rating from that multiple on any growth wobble Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

ELV Stock: Elevance Beat AND Raised Guidance — So Why Did It Fall?

Elevance Health (ELV) Q2 2026 — Elevance Health (ELV), one of the largest U.S. health insurers (~46M members, formerly Anthem), reported Q2 2026 adjusted EPS of $7.45, crushing the $6.18 estimate (helped by Carelon pharmacy) — but that was down from $8.84 a year ago, and the stock FELL. Despite the beat, it RAISED full-year adjusted EPS guidance to at least $27.00. The problem: a rising medical loss ratio (surging medical costs) has earnings falling YoY, and the market doubts the beat is sustainable. The stock (~$373, ~14x forward) is ~15% off its $436 high, off a $274 low. Here's a puzzle: Elevance Health (formerly Anthem) — a ~46-million-member health-insurance giant — just beat earnings AND raised its full-year guidance to at least $27/share, and the stock fell anyway. Why? Because underneath the beat is a rising medical loss ratio: members are using more care than the company priced for, so margins are compressing and adjusted EPS ($7.45) is down sharply from $8.84 a year ago. The beat was against a lowered bar, and the market doubts it's sustainable. It's a sector-wide storm (utilization, Medicare Advantage, Medicaid) hitting all managed care. The bull case: a scaled, essential insurer at ~14x (a cyclical trough), with a growing fee-based Carelon arm, that just raised guidance — the Street sees ~17% upside ($438 target) if costs peak. The bear case: earnings are falling and the MLR is still rising. Our owner-earnings work lands near $390 (vs $373) — modest upside if costs normalize. Our call: HOLD, 3/5 — cheap and raising guidance, but medical costs are the swing. Watch the MLR; add near the lows. Not financial advice. THE CALL: HOLD (3/5, CHEAP AND RAISING GUIDANCE, BUT MEDICAL COSTS ARE THE SWING) — base-case value ~$390 vs ~$373 today. What to watch: the medical loss ratio (MLR) flattening and then falling — the single number that proves costs have peaked and the earnings recovery is real; the risk is a future guidance cut if costs keep rising Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

JNJ Stock: A $100 Billion Milestone — But Is the Fortress Fully Priced?

Johnson & Johnson (JNJ) Q2 2026 — Johnson & Johnson (JNJ) reported a clean Q2 2026 beat: sales +6.6% to $25.3B, adjusted EPS $2.90 (+4.7%, ahead of estimates), with Innovative Medicine (pharma) sales +6.8% out-growing the patent cliffs. It RAISED full-year guidance to ~$101.1B sales (+7.3%) and $11.68 adjusted EPS (+8.2%) — on track to cross $100B in annual revenue for the first time in its 140-year history. The AAA-rated Dividend King (~250) has recovered strongly off its ~$162 low to ~7% below its ~$269 high, and rose on the print. Johnson & Johnson is the ultimate healthcare fortress — a diversified, AAA-rated giant (one of only a handful on earth) with two engines (Innovative Medicine pharma + MedTech devices) and a 60+ year dividend-increase streak. In Q2 2026 it beat (sales +6.6% to $25.3B, adjusted EPS $2.90) and RAISED guidance to ~$101.1B sales and $11.68 adjusted EPS — crossing $100B in annual revenue for the first time in 140 years. The pharma engine (+6.8%) is out-growing the Stelara-style patent cliffs, which is the whole long-term debate. The overhangs are talc litigation and drug-pricing policy, and after recovering near its highs it trades at ~21x forward for ~8% growth — full, not cheap. Our owner-earnings work lands near $260 (vs ~$250), below the Street's ~$272. Our call: HOLD, 3/5 — a beat-and-raise from a fortress at a fair price; own it for resilience and the ~3% AAA-backed dividend, add on talc-driven dips. Not financial advice. THE CALL: HOLD (3/5, A HEALTHCARE FORTRESS, BEAT AND RAISED, AT A FAIR PRICE) — base-case value ~$260 vs ~$250 today. What to watch: a clean, capped talc-litigation settlement (removing the biggest overhang), continued pharma-pipeline launches out-growing the Stelara patent cliff, and talc-headline dips toward the low $230s as add points Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.